Clinical significance hormone receptor(ER/PR), cerbB-2 of neoadjuvant chemotherapy in breast cancer

Objective: To explore the expression and its clinical significance of hormone receptor and cerbB-2 in breast cancer tissue received neoadjuvant chemotherapy. Methods: The estrogen receptor(ER), progesterone recepter(PR) and cerbB-2 in breast cancer tissue of 89 patients received neoadjuvant chemotherapy were detected by immunohistochemical method, and analysed the relation with response of neoadjuvant chemotherapy. Results: The overall response rate of neoadjuvant chemotherapy on breast cancer was 89. 9%, of which the complete response was 32. 6%, partial response was 57. 3%, pathological complete response was 17. 9%, disease stable 10. 5%. Hormonal receptor expressions was significantly related to treatment response,the pathological complete response rate was 27. 2% in ER/PR negative tumors,but it was 7.1% in the positive tumors (P0. 05). No correlation was observed between the treatment response and cerbb-2 expression. Conclusions: There has higher sensitivity to neoadjuvant chemotherapy in hormonal receptor negative tumors. The hormone receptor of breast cancer in neoadjuvant chemotherapy may be provide important index in decision sensitivity of chemotherapy and clinical evaluation.